With 24.5 million people around the world on antiretroviral treatment for HIV, more and more countries are switching to dolutegravir-based regimens. Ensuring access to this simpler, better tolerated treatment requires a broad number of stakeholders working in partnership.

In this panel discussion leading up to the 23rd International AIDS Conference, the Medicines Patent Pool (MPP) brings together some of the key players that made scale-up possible. Under the moderation of Marie-Paule Kieny, the Chair of MPP Board, the panel discussion will provide an opportunity to focus on lessons learned to date on access to dolutegravir and the fixed-dose combination TLD.

MPP’s voluntary licensing mechanism and the partnership has resulted in access to generic DTG-based treatments for nearly 8 million people living with HIV in nearly 100 low- and middle-income countries by 2020 and in 131 countries for pediatric use. Furthermore, in the current COVID-19 pandemic, participants will reflect on lessons learned from the HIV experience that can be applied to the fight against COVID-19.